Physician profile

Hershel Garner

Radiation Oncology · Fayetteville, AR

NPI 1508839572

$2,358.14

in general payments reported to CMS, 2019-2025

47 companies · $315 in 2025

The $315 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,744.11

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Daiichi Sankyo INC. $243.24 2021-2025 Enhertu, Datroway
Novartis Pharmaceuticals Corporation $205.67 2021-2025
Puma Biotechnology, INC. $191.93 2023-2025
Merck Sharp & Dohme LLC $190.29 2022-2025 Keytruda, Lynparza
Janssen Biotech, INC. $152.59 2021-2025 Rybrevant, Darzalex, Imbruvica
Eisai INC. $136.21 2021-2024
Tersera Therapeutics LLC $96.87 2022-2023 Xermelo, Zoladex
Regeneron Healthcare Solutions, INC. $94.34 2022-2024 Libtayo
Seagen INC. $62.45 2020-2023 Tukysa, Adcetris
Iovance Biotherapeutics, INC. $47.37 2024-2025 Amtagvi
Genmab U.S., INC. $42.01 2024 Epkinly
Ipsen Biopharmaceuticals, INC $41.89 2022-2023 Tazverik, Onivyde
Lilly USA, LLC $39.54 2023-2024 Verzenio, Jaypirca
G1 Therapeutics, INC. $39.14 2022-2023 Cosela
Exelixis INC. $38.45 2023-2024 Cabometyx
Show all 47 companies
CompanyGeneral paymentsYearsTop products
Bayer Healthcare Pharmaceuticals INC. $37.81 2020-2024
Genzyme Corporation $36.58 2020-2021
Rigel Pharmaceuticals, INC. $36.53 2022-2023 Tavalisse, Rezlidhia
Aveo Pharmaceuticals, INC. $35.00 2022-2025
Incyte Corporation $33.41 2024-2025 Monjuvi, Jakafi
Pharmacosmos Therapeutics INC. $32.55 2024 Cosela
Novocure INC. $29.89 2023 Optune
Jazz Pharmaceuticals INC. $29.79 2023-2024
Sobi, INC $29.49 2023-2024
Kyowa Kirin, INC. $29.01 2019-2025
Astrazeneca Pharmaceuticals LP $27.95 2023-2024 Enhertu
Emd Serono, INC. $26.36 2020-2023 Tepmetko
Boehringer Ingelheim Pharmaceuticals, INC. $26.14 2021
Morphosys, US INC. $25.74 2021-2023 Monjuvi
Pharmacyclics LLC, An Abbvie Company $24.81 2023 Epkinly
Beigene USA, INC. $24.70 2020-2021
Taiho Oncology, INC. $23.52 2023
Brainlab, INC. $22.19 2019
Fortovia Therapeutics, INC. $21.23 2019
Geron Corporation $19.00 2025 Rytelo
Pharmaessentia USA Corporation $17.64 2023 Besremi
Recordati_rare_diseases_inc. $16.65 2024 Sylvant
Blueprint Medicines Corporation $14.84 2025 Ayvakit
Astellas Pharma US INC $14.41 2024 Padcev
Acceleron Pharma, INC. $13.84 2020
Mylan Institutional INC. $13.42 2022
Pfizer INC. $13.07 2024
Spectrum Pharmaceuticals INC. $12.69 2023 Rolvedon
Cti Biopharma Corp. $12.69 2023 Vonjo
Varian Medical Systems, INC. $12.30 2019
Coherus Oncology, INC. $11.86 2021
Glaxosmithkline, LLC. $11.04 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Hershel Garner

$2,358.14

in general payments reported 2019-2025

Years
2019-2025
Top company
Daiichi Sankyo INC.
Context
The $315 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).

https://glasscript.com/doctor/1004044/hershel-garner

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.